Literature DB >> 8611436

Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma--frequency of specific banding patterns at non-diagnostic serum levels.

S Ho1, P Cheng, J Yuen, A Chan, N Leung, W Yeo, T Leung, W Y Lau, A K Li, P J Johnson.   

Abstract

Serum levels of alphafetoprotein are raised in 60-80% of patients with hepatocellular carcinoma. Although widely used as a serum marker, frequent false-positive results in patients with benign liver disease, result in poor specificity. This occurs particularly when levels of alphafetoprotein fall between 50-500 ng ml-1, the so-called 'grey area'. Recent reports suggest that isoelectric focusing of alphafetoprotein demonstrates certain bands that are more specific for hepatocellular carcinoma. Our aim was to determine whether the apparent specificity of this new approach is gained at the expense of decreased sensitivity. Sera from 110 patients with a 'non-diagnostic' serum alphafetoprotein level (50-500 ng ml-1) were examined by isoelectric focusing and quantified by densitometric scanning. Ten patients with chronic liver disease and a raised serum alphafetoprotein level (50-500 ng ml-1), but with no evidence of hepatocellular carcinoma, were also studied. Isoelectric focusing revealed characteristic hepatocellular carcinoma bands (bands +II and +III) in 96% patients overall, and 100% of those with levels of total alphafetoprotein greater than 100 ng ml-1. No such bands were seen among ten subjects with cirrhosis but without hepatocellular carcinoma. Bands that are characteristic of hepatocellular carcinoma (bands +II or +III) are seen in the great majority of hepatocellular carcinoma patients; their absence makes a diagnosis of hepatocellular carcinoma extremely unlikely.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611436      PMCID: PMC2075834          DOI: 10.1038/bjc.1996.192

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

Review 1.  Alpha-fetoprotein molecular heterogeneity. Physiologic correlations with normal growth, carcinogenesis and tumor growth.

Authors:  C J Smith; P C Kelleher
Journal:  Biochim Biophys Acta       Date:  1980-03-12

2.  Heterogeneity of human alpha-fetoprotein as revealed by isoelectric focusing in urea-containing gels.

Authors:  E P Lester; J B Miller; S Yachnin
Journal:  Biochim Biophys Acta       Date:  1978-09-26

3.  Germ cell tumors express a specific alpha-fetoprotein variant detectable by isoelectric focusing.

Authors:  P J Johnson; S Ho; P Cheng; A Chan; T Leung; J Yuen
Journal:  Cancer       Date:  1995-04-01       Impact factor: 6.860

4.  Structure of the asparagine-linked sugar chains of alpha-fetoprotein purified from human ascites fluid.

Authors:  H Yoshima; T Mizuochi; M Ishii; A Kobata
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

5.  Carbohydrate structure of the concanavalin A molecular variants of alpha-fetoprotein.

Authors:  T Krusius; E Ruoslahti
Journal:  J Biol Chem       Date:  1982-04-10       Impact factor: 5.157

6.  Sugar chain of alpha-fetoprotein produced in human yolk sac tumor.

Authors:  K Yamashita; A Hitoi; Y Tsuchida; S Nishi; A Kobata
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

7.  Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection.

Authors:  P J Johnson; R Williams
Journal:  J Natl Cancer Inst       Date:  1980-06       Impact factor: 13.506

8.  Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma.

Authors:  P J Johnson; B Portmann; R Williams
Journal:  Br Med J       Date:  1978-09-02

9.  alpha-fetoprotein in noneoplastic hepatic disorders.

Authors:  J R Bloomer; T A Waldmann; K R McIntire; G Klatskin
Journal:  JAMA       Date:  1975-07-07       Impact factor: 56.272

10.  Distinct molecular species of human alpha-fetoprotein due to differential affinities to lectins.

Authors:  K Taketa; M Izumi; E Ichikawa
Journal:  Ann N Y Acad Sci       Date:  1983       Impact factor: 5.691

View more
  4 in total

1.  Grey Turner Memorial Lecture. Changing role of liver surgeons.

Authors:  A K Li
Journal:  World J Surg       Date:  1999-01       Impact factor: 3.352

2.  'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.

Authors:  P J Johnson; N Leung; P Cheng; C Welby; W T Leung; W Y Lau; S Yu; S Ho
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Structures of disease-specific serum alpha-fetoprotein isoforms.

Authors:  P J Johnson; T C Poon; N M Hjelm; C S Ho; C Blake; S K Ho
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

4.  Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour.

Authors:  P J Johnson; T C Poon; N M Hjelm; C S Ho; S K Ho; C Welby; D Stevenson; T Patel; R Parekh; R R Townsend
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.